The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

The European Commission approved Johnson and Johnson’s Yuvanci as the first single-pill combination therapy for PAH.

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in ...

Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...

Valerio Therapeutics, a developer of DNA Decoy therapeutics, has announced its acquisition of Emglev Therapeutics, a company ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

LEO Pharma has submitted a New Drug Application (NDA) to China's National Medical Products Administration for Enstilar, ...

Medidata is a winner in the Innovation, and Product Launches categories in the 2024 Pharmaceutical Technology Excellence ...

SK pharmteco, a contract development and manufacturing organisation, has announced an investment of $260m to expand its small ...

The MediLedger Project utilises blockchain technology to tackle counterfeit drugs. The project uses blockchain to track and ...